

# Waning of SARS-Cov-2 vaccine effectiveness against delta variant in COPD patients

Lorinc Polivka<sup>1</sup>, Istvan Valyi-Nagy<sup>2</sup>, Zoltan Szekanecz<sup>3</sup>, Krisztina Bogos<sup>4</sup>, Hajnalka Vago<sup>1</sup>, Anita Kamondi<sup>5</sup>, Ferenc Fekete<sup>6</sup>, Janos Szlavik<sup>2</sup>, György Surjan<sup>7</sup>, Orsolya Surlyan<sup>7</sup>, Peter Nagy<sup>8</sup>, Zsuzsa Schaff<sup>1</sup>, Zoltan Kiss<sup>9</sup>, Cecilia Müller<sup>7</sup>, Miklos Kasler<sup>10</sup>, and Veronika Müller<sup>1</sup>

<sup>1</sup>Semmelweis University

<sup>2</sup>Central Hospital of Southern Pest

<sup>3</sup>University of Debrecen

<sup>4</sup>National Korányi Institute of Pulmonology

<sup>5</sup>National Institute of mental Health, Neurology and Neurosurgery

<sup>6</sup>Heim Pál National Pediatric Institute

<sup>7</sup>National Center for Public Health

<sup>8</sup>National Institute of Oncology

<sup>9</sup>University of Pécs

<sup>10</sup>Ministry of Interior

April 20, 2023

## Abstract

Although, the COVID-19 pandemic is profoundly changing, data on the effect of vaccination and duration of protection can still be advantageous, especially for patients with COPD, who are more vulnerable to respiratory infections. The Hungarian-COVID-19 registry was retrospectively investigated for vaccine effectiveness (VE) and daily risk for infection and hospitalization by time since the last vaccination and vaccine type in adults with COPD diagnosis and an exact-matched control group during the Delta VOC wave in Hungary. For the matching sex, age, major comorbidities, vaccination status, and prior infection was used on August 23, 2021. The study population included 373 962 cases divided into COPD patients (age: 66.67±12.66) and a 1:1 matched group (age: 66.73±12.67). In both groups, the female/male ratio was 52.2:47.7. There was no significant difference between the groups in daily risks for infection or hospitalization among the unvaccinated. Regarding vaccinated cases, a faster decline of effectiveness was noted for hospitalization prevention in the COPD group regardless of vaccine type. The VE reduction in this group was from 90.1% (mRNA) and 87.8% (other) to 48.8% and 34.1% respectively in 180 days. Based on the time-stratified multivariate Cox analysis of the vaccinated cases, the hazard ratio was 1.09 (95% CI: 1.05-1.14) for infection and 1.87 (95% CI: 1.59-2.19) for hospitalization in the COPD group. Based on our study COPD patients are at higher risk for SARS-Cov2 VE waning and have altogether a higher risk for infection and need for hospitalization emphasizing suggestion for revaccination measures in this patient population.

## Hosted file

Polivka L et al COPD vaccine effectiveness\_wiley.docx available at <https://authorea.com/users/609523/articles/638896-waning-of-sars-cov-2-vaccine-effectiveness-against-delta-variant-in-copd-patients>

